172 related articles for article (PubMed ID: 11272609)
41. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
42. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation.
Chuhjo T; Yachie A; Kanegane H; Kimura H; Shiobara S; Nakao S
Am J Hematol; 2003 Apr; 72(4):255-8. PubMed ID: 12666136
[TBL] [Abstract][Full Text] [Related]
43. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD;
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
[TBL] [Abstract][Full Text] [Related]
44. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study.
Liu X; Wu M; Peng Y; Chen X; Sun J; Huang F; Fan Z; Zhou H; Wu X; Yu G; Zhang X; Li Y; Xiao Y; Song C; Xiang AP; Liu Q
Cell Transplant; 2014; 23(9):1087-98. PubMed ID: 23294601
[TBL] [Abstract][Full Text] [Related]
45. [An analysis of risk factors and prognosis of Epstein-Barr virus infection after allogeneic hematopoietic stem cell transplantation].
Zhang Q; Zou BH; Lou X; Liu H; Zhang B; Chen H
Zhonghua Nei Ke Za Zhi; 2016 Aug; 55(8):619-23. PubMed ID: 27480556
[TBL] [Abstract][Full Text] [Related]
46. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
47. Utility of quantitative EBV DNA measurements in cerebrospinal fluid for diagnosis and monitoring of treatment of central nervous system EBV-associated post-transplant lymphoproliferative disorder after allogenic hematopoietic stem cell transplantation.
Bocian J; Januszkiewicz-Lewandowska D
Ann Transplant; 2014 May; 19():253-6. PubMed ID: 24866354
[TBL] [Abstract][Full Text] [Related]
48. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
[TBL] [Abstract][Full Text] [Related]
49. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
Ru Y; Chen J; Wu D
Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932
[TBL] [Abstract][Full Text] [Related]
51. T-cell lymphoma with a granulomatous lesion of the lungs after autologous hematopoietic stem cell transplantation for Epstein-Barr virus-positive diffuse large B-cell lymphoma: a unique rare case of metachronous B-cell and T-cell lymphoma.
Kajimoto Y; Terasaki Y; Terasaki M; Kunugi S; Okabe Y; Wakita S; Inokuchi K; Shimizu A
Diagn Pathol; 2020 Oct; 15(1):125. PubMed ID: 33036636
[TBL] [Abstract][Full Text] [Related]
52. High doses of mother's lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood.
Wang Q; Liu H; Zhang X; Liu Q; Xing Y; Zhou X; Tong C; Zhu P
Blood; 2010 Dec; 116(26):5941-7. PubMed ID: 20926772
[TBL] [Abstract][Full Text] [Related]
53. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
54. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.
Juvonen E; Aalto SM; Tarkkanen J; Volin L; Mattila PS; Knuutila S; Ruutu T; Hedman K
Bone Marrow Transplant; 2003 Jul; 32(1):97-102. PubMed ID: 12815484
[TBL] [Abstract][Full Text] [Related]
55. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
Chiereghin A; Bertuzzi C; Piccirilli G; Gabrielli L; Squarzoni D; Turello G; Ferioli M; Sessa M; Bonifazi F; Zanoni L; Sabattini E; Lazzarotto T
Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
[TBL] [Abstract][Full Text] [Related]
56. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
[TBL] [Abstract][Full Text] [Related]
57. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation.
McGuirk JP; Seropian S; Howe G; Smith B; Stoddart L; Cooper DL
Bone Marrow Transplant; 1999 Dec; 24(11):1253-8. PubMed ID: 10642818
[TBL] [Abstract][Full Text] [Related]
58. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
[TBL] [Abstract][Full Text] [Related]
59. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
60. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.
Weinstock DM; Ambrossi GG; Brennan C; Kiehn TE; Jakubowski A
Bone Marrow Transplant; 2006 Mar; 37(6):539-46. PubMed ID: 16462755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
